Domestic pharma companies eye robust growth from US market in FY20

Domestic pharmaceutical companies are expecting buoyant growth from the US market in FY20 on the back of product launches, easing of price erosion and withdrawal of certain drugs by top companies.

The generics drug business has been showing signs of stability over the past few months. 

While companies continue to face regulatory pressure leading to higher costs, they see an uptick from the launch of differentiated and high-margin products. “We expect FY20 to be fairly strong with most of our focused markets expected to show reasonable growth in the coming financial year . Our growth will be driven by wider portfolio, limited